Add like
Add dislike
Add to saved papers

The effects of terlipressin and direct portacaval shunting on liver hemodynamics following 80% hepatectomy in the pig.

Liver failure is the major cause of death following liver resection. Post-resection portal venous pressure (PVP) predicts liver failure, is implicated in its pathogenesis and when PVP is reduced, rates of liver dysfunction decrease. The aim of this study was to characterize the hemodynamic, biochemical and histological changes induced by 80% hepatectomy in non-cirrhotic pigs and determine if terlipressin or direct portacaval shunting can modulate these effects.Pigs were randomized (n=8/group) to undergo 80% hepatectomy alone (control); terlipressin (2 mg bolus + 0.5-1 mg/h) + 80% hepatectomy; or portacaval shunt (PCS) + 80% hepatectomy, and were maintained under terminal anesthesia for 8 hours. The primary outcome was change in PVP. Secondary outcomes included portal venous flow (PVF), hepatic arterial flow (HAF), and biochemical and histological markers of liver injury. Hepatectomy increased PVP (9.3±0.4 mm Hg pre-hepatectomy vs. 13.0±0.8 mm Hg post-hepatectomy, p<0.0001) and PVF/g liver (1.2±0.2 ml/min/g vs. 6.0±0.6 ml/min/g, p<0.0001) and decreased HAF (70.8±5.0 ml/min vs. 41.8±5.7 ml/min, p=0.0024). Terlipressin and PCS reduced PVP (terlipressin=10.4±0.8 mm Hg, p=0.0459 and PCS=8.3±1.2 mm Hg, p=0.0247) and PVF (control=869.0±36.1 ml/min vs terlipressin=565.6±25.7 ml/min, p<0.0001 and PCS=488.4±106.4 ml/min, p=0.0022) compared with control. Treatment with terlipressin increased HAF (73.2±11.3 ml/min) compared with control (40.3±6.3 ml/min, p=0.0260). The results of this study suggest that terlipressin and PCS may have a role in the prevention and treatment of post-resection liver failure.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app